Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998–2003)

Diagnostic Microbiology and Infectious Disease - Tập 52 Số 3 - Trang 265-273 - 2005
Hélio S. Sader1,2, Thomas R. Fritsche2, Ronald N. Jones2,3
1Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo 04023-900, Brazil
2JMI Laboratories, North Liberty, IA 52317, USA
3Tufts University School of Medicine, Boston, MA 02111 USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Bantar, 2002, Acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from a South American working group (ConsenSur), J. Chemother., 14, 635, 10.1179/joc.2002.14.6.635

Barradell, 1994, Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs, 47, 471, 10.2165/00003495-199447030-00007

Bouza, 2000, Monotherapy versus combination therapy for bacterial infections, Med. Clin. North Am., 84, 1357, 10.1016/S0025-7125(05)70293-5

Carmeli, 1999, Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents, Antimicrob. Agents Chem., 43, 1379, 10.1128/AAC.43.6.1379

Chapman, 2003, Cefepime: A review of its use in the management of hospitalized patients with pneumonia, Am. J. Respir. Medicine, 2, 75, 10.1007/BF03256641

2005

Fritsche, 2003, Diagn. Microbiol. Infect. Dis., 47, 435, 10.1016/S0732-8893(03)00114-7

Hanberger, 2001, Surveillance of antibiotic resistance in European ICUs, J. Hosp. Infect., 48, 161, 10.1053/jhin.2001.0987

Harris, 2002, Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients, Clin. Infect. Dis., 34, 340, 10.1086/338237

Ibrahim, 2000, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, 146, 10.1378/chest.118.1.146

Jones, 2001, Resistance patterns among nosocomial pathogens. Trends over the past few years, Chest, 119, 397S, 10.1378/chest.119.2_suppl.397S

Jones, 2002, Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001), Diagn. Microbiol. Infect. Dis, 44, 379, 10.1016/S0732-8893(02)00442-X

Kessler, 2001, Cefepime microbiologic profile and update, Pediatr. Infect. Dis. J., 20, 331, 10.1097/00006454-200103000-00031

Mandell, 2003, Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America, Clin. Infect. Dis., 37, 1405, 10.1086/380488

2003

Newhauser, 2003, Antibiotic resistance among gram-negative bacilli in US intensive care units, JAMA, 289, 885, 10.1001/jama.289.7.885

Sader, 2003, Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997–2001), Diagn. Microbiol. Infect. Dis., 47, 361, 10.1016/S0732-8893(03)00052-X

Sader, 1992, Historical overview of the cephalosporin spectrum: Four generations of structural evolution, Antimicrob. Newsl., 8, 75, 10.1016/0738-1751(92)90022-3

Troillet, 1997, Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns, Clin. Infect. Dis., 25, 1094, 10.1086/516092